Exploring beyond numeric weight loss: The metabolic effects of semaglutide

The use of semaglutide resulted in reductions of 3.5% in total fat mass and 2.0% in visceral fat mass while increasing lean body mass by 3.0%.

• Semaglutide is associated with significant reductions in hemoglobin A1C, with decreases of 1.2-1.5% for the 0.5 mg dose and 1.4-1.8% for the 1.0 mg dose.
• It uniquely reduces Low-Density Lipoprotein and total cholesterol levels, with mean differences of -0.16 mmol/L and -0.48 mmol/L, respectively.
• Withdrawal of semaglutide is linked to weight regain, while continued treatment is associated with further weight loss.
• Semaglutide may decrease hunger and increase feelings of fullness, leading to lower energy intake.
• The treatment could help in managing weight regain after failed bariatric surgery.

AI simplified